Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
17 December 2022 - 09:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December 2022
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
(Registrant’s name)
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b) (1): ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b) (7): ¨
Incorporation By Reference
This report on Form 6-K is hereby incorporated by reference
into the Company’s registration statements
on Form S-8 (file
No. 333-259748), Form F-3 (file
No. 333-256630), Form S-8 (file
No. 333-238679), and Form S-8 (file No. 333-265413).
Explanatory Note:
The Registrant is filing this Report on Form 6-K to report its
financial results for the six months ended June 30, 2022
and to discuss its recent corporate developments. The current
composition of the board, the management team, and the committees
are as shown below:
Members of the
Board of Directors |
Members of the
Management team |
Members of the
Audit Committee |
Members of the
Nomination
Committee |
Members of the
Remuneration
Committee |
Haohan Xu (Chairman) |
Haohan Xu (Co-CEO) |
Tianruo Pu (Chairperson) |
Honggang Tian
(Chairperson) |
Zhigang Zhao
(Chairperson) |
Honggang Tian |
Chris Chang Yu (Co-CEO) |
Zhigang Zhao |
Tianruo Pu |
Tianruo Pu |
Xiaoyu Li |
Xiaoyu Li (Co-CFO) |
Honggang Tian |
Zhigang Zhao |
Honggang Tian |
Tianruo Pu |
Jinqiu Tang (Co-CFO) |
- |
- |
- |
Zhigang Zhao |
Xingyan Gao (Secretary) |
- |
- |
- |
Attached as exhibit 99.1 to this Report on Form 6-K is the
press release dated December 16, 2022:
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this current report with respect to the Company’s
current plans, estimates, strategies and beliefs and other
statements that are not historical facts are forward-looking
statements about the future performance of the Company.
Forward-looking statements include, but are not limited to, those
statements using words such as “believe,” “expect,” “plans,”
“strategy,” “prospects,” “forecast,” “estimate,” “project,”
“anticipate,” “aim,” “intend,” “seek,” “may,” “might,” “could” or
“should,” and words of similar meaning in connection with a
discussion of future operations, financial performance, events or
conditions. From time to time, oral or written forward-looking
statements may also be included in other materials released to the
public. These statements are based on management’s assumptions,
judgments and beliefs in light of the information currently
available to it. The Company cautions investors that a number of
important risks and uncertainties could cause actual results to
differ materially from those discussed in the forward-looking
statements, including but not limited to, product and service
demand and acceptance, changes in technology, economic conditions,
the impact of competition and pricing, government regulation, and
other risks contained in reports filed by the company with the
Securities and Exchange Commission. Therefore, investors should not
place undue reliance on such forward-looking statements. Actual
results may differ significantly from those set forth in the
forward-looking statements.
All such forward-looking statements, whether written or oral, and
whether made by or on behalf of the company, are expressly
qualified by the cautionary statements and any other cautionary
statements which may accompany the forward-looking statements. In
addition, the company disclaims any obligation to update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Exhibit Index:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
|
AnPac Bio-Medical Science
Co., Ltd. |
|
|
(Registrant) |
|
|
|
Date: December 16,
2022 |
By: |
/s/ Haohan Xu |
|
Name: |
Haohan Xu |
|
Title: |
Co-Chief Executive Officer |
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Feb 2023 to Mar 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2022 to Mar 2023